Nagoya Pharmaceutical Corporate Pension Fund

Nagoya Pharmaceutical Corporate Pension Fund

The Nagoya Pharmaceutical Corporate Pension Fund was established in 1970 as a dedicated corporate pension vehicle for employees within Japan's pharmaceutical and related industries. Its coverage spans three prefectures — Aichi, Mie, and Gifu — and its participating employers include pharmaceutical-related firms such as Mediceo Corporation, Nakakita Yakuhin, Amano Enzyme, Hoyu, and Yagami. Chairman Hiroaki Takagi leads the fund alongside Managing Director Masaichi Yamada, operating from the Nagoya Pharmaceutical Building in central Nagoya.\n\nThe fund runs a notably broad private-markets program for a Japanese corporate pension of its size. Its strategy spans buyouts, CLOs, distressed debt, and venture capital — covering the full spectrum from seed and early-stage to expansion and late-stage. Rather than concentrating entirely on domestic allocations, the portfolio construction implies a mixture of fund commitments and direct exposure across global private markets. The inclusion of CLOs and distressed debt alongside early-stage venture indicates a liquidity-aware approach that layers illiquidity premiums across multiple return drivers.\n\nThe fund shares infrastructure and governance ties with the Nagoya Pharmaceutical Health Insurance Association, a co-located sister organization serving the same regional pharmaceutical workforce. It also owns the Nagoya Pharmaceutical Building, a commercial property at 3-1-35 Marunouchi that provides a steady real-asset anchor for the plan. The fund is a member of the Pension Fund Association of Japan, the national body representing corporate pension plans.\n\nWhat distinguishes this plan from many similarly sized Japanese corporate pensions is its explicit mandate across the full venture lifecycle — from seed to late-stage — paired with credit instruments like CLOs and distressed debt. Most Japanese corporate plans of this vintage remain heavily anchored in domestic fixed income; the Nagoya Pharmaceutical Corporate Pension Fund instead runs a multi-asset private-markets program that mirrors the allocation patterns more commonly seen at larger North American or European institutional investors.